Int J Ayu Pharm Chem
ISSN 2350-0204
www.ijapc.com

REVIEW ARTICLE

Clinical Utility and Future Frontiers of Biological Age Estimators

Author: Naina Joshi[1]

Co Authors: Chhaju Ram Yadav[2]

[1,2]Department of Kriya Sharira, National Institute of Ayurveda, Jaipur, Rajasthan, India

ABSTRACT

As global life expectancy increases, the disparity between chronological age (CA) and physiological health termed health-span has become a critical focal point for geroscience. CA is an imprecise proxy for senescence, failing to account for the stochastic nature of cellular degradation and individual lifestyle variations. This article evaluates the transition from phenotypic markers to high-resolution molecular clocks as superior metrics for quantifying aging. We comprehensively review calculation methodologies, ranging from clinical composite scores to contemporary third-generation epigenetic clocks like DunedinPACE. By synthesizing current data, we examine the integration of artificial intelligence (AI) in processing multi-omic datasets, including transcriptomics and proteomic signatures. Despite their predictive power, challenges regarding tissue-specific aging and clinical standardization persist. This review argues that biological age (BA) should be integrated into routine clinical practice to transition from reactive to proactive, personalized medicine.

Key Words *Biological Age, Epigenetic Clocks, Geroscience, Multi-omics, Artificial Intelligence*

Received 13th April 2026 Accepted 25th June 2026 Published 10th July 2026

INTRODUCTION

The discrepancy between birth date and physiological integrity defines the field of geroscience. While CA remains the primary risk factor for chronic disease, the emergence of fast agers highlights the need for a granular metric that reflects actual health status[1,2]. Biological age (BA) represents the cumulative molecular and cellular damage within an organism[3]. Current literature suggests that BA is a significantly stronger predictor of morbidity and hospital mortality than CA[4]. The objective of this review is to evaluate the evolution of BA estimation, from early clinical models to modern AI-driven omics and to outline the future scope of longevity medicine[5,6].

The above diagram (Figure 1) illustrates the divergence between chronological age (linear, x-axis) and biological age (variable curve, y-axis). The "Fast Ager" trajectory accumulates damage faster than time elapsed, crossing the disease threshold earlier, while the "Slow Ager" trajectory maintains physiological resilience.

Int J Ayu Pharm Chem
ISSN 2350-0204
www.ijapc.com

REVIEW ARTICLE

METHODS

This narrative review employed a systematic search strategy using online databases like PubMed, Scopus, and DHARA (Digital Helpline for Ayurveda Research Articles). A comprehensive search was conducted for articles including the keywords Biological Age, Telomerase Activators, and Oxidative Stress.



Figure 1 Trajectory of Biological vs. Chronological Age

The above diagram (Figure 1) illustrates the divergence between chronological age (linear, x-axis) and biological age (variable curve, y-axis). The "Fast Ager" trajectory accumulates damage faster than time elapsed, crossing the disease threshold earlier, while the "Slow Ager" trajectory maintains physiological resilience.

RESULTS

Methodological Approaches to Estimation

Current estimation methods are categorized into three primary evolutionary pillars:

Clinical Composite Models- These utilize standard laboratory tests (e.g., albumin, creatinine, glucose) integrated via algorithms like the Klemera-Doubal Method (KDM)[7] or PhenoAge[8]. These models are highly accessible and show better correlation with physical function than CA, making them suitable for low-resource clinical settings[8].

Epigenetic Clocks (DNA Methylation)- The "gold standard" of measurement utilizes DNA methylation (DNAm) patterns at specific CpG sites.

- **First Generation:** Trained to predict CA (e.g., Horvath Clock, Hannum Clock)[9,10].
- **Second Generation:** Trained to predict mortality and healthspan (e.g., DNAm GrimAge)[11].

REVIEW ARTICLE

- **Third Generation:** Measures the "velocity" of aging (e.g., DunedinPACE), acting as a speedometer for cellular decline[12].

Multi-Omics and AI- Modern approaches utilize transcriptomics (RNA-sequencing), proteomics, and metabolomics to create systemic aging profiles[13,14]. Deep Learning models now analyze non-invasive data like retinal scans and facial features to estimate BA with high precision[15,16].



Figure 2 AI-Driven Multi-Omics Integration

Figure 2 illustrates a schematic representation of how modern Deep Learning models aggregate high-dimensional inputs—ranging from molecular signatures (DNA methylation, RNA-sequencing) to non-invasive digital biomarkers (retinal scans)—to generate a composite Biological Age score.

Empirical Evidence and Clinical Utility

Synthesis of recent clinical data reveals three primary domains of efficacy for biological age estimators over traditional chronological metrics.

Predictive Superiority and Mortality Risk- BA measures significantly outperform CA in predicting health outcomes. Second-generation clocks, specifically DNAm GrimAge, have demonstrated a Hazard Ratio (HR) of approximately 1.10 per year of age acceleration[11]. This indicates that for every one year an individual's BA exceeds their CA, their risk of all-cause mortality increases by 10%. Furthermore, individuals with accelerated "retinal ages" show a 2% increase in all-cause mortality and a 3% increase in cardiovascular-specific mortality for every 1-year increase in the age gap[15].

Sensitivity to Interventions- Unlike CA, BA metrics are dynamic. Results from the CALERIE trial indicated that moderate caloric restriction slowed the pace of aging, as measured by DunedinPACE, by 2–3%[12,17]. Additionally, the TRIIM trial, utilizing a protocol of growth hormone and metformin, reported a mean decrease in epigenetic age by 1.5 years after one

REVIEW ARTICLE

year of treatment, suggesting potential reversibility of biological decline[18].

AI-Driven Diagnostic Precision- Deep Learning has revolutionized the accessibility of BA testing. AI models analyzing standard Complete Blood Count (CBC) data (e.g., Aging.AI) can predict BA with a Mean Absolute Error (MAE) of just 5.9 years[19]. Gradient Boosting models using 27 clinical factors have achieved an R^2 of 0.967, identifying kidney and liver function as the most weighted predictors of physiological decline[14].

Table 1 Comparison of Key Biological Age Estimators

Estimator Type	Key Biomarkers	Primary Outcome	Clinical Accessibility
Horvath Clock (1st Gen)	DNA Methylation	Chronological Age	Low (High Cost)
GrimAge (2nd Gen)	DNAm + Plasma Proteins	Mortality / Healthspan	Low (High Cost)
DunedinPACE (3rd Gen)	DNAm (Pace of Aging)	Rate of Decline	Low (High Cost)
PhenoAge	Clinical Blood Markers	Mortality Risk	High (Routine Labs)
Aging.AI	CBC / Blood Panel	Biological Age	Very High (Digital)

The different types of biological age estimators, the biomarkers utilised by them, the outcomes assessed and the feasibility of their utilisation in clinical settings has been compared in Table 1.

DISCUSSION

The findings presented in this review underscore a pivotal shift in geroscience: the transition of BA from a theoretical construct to a validated clinical tool. However, several critical barriers and future directions must be addressed.

The Challenge of Tissue Heterogeneity- One of the most significant complexities is that aging is not a synchronized, systemic process. Recent "organ-clock" studies have demonstrated that different physiological systems within the same individual can age at vastly different rates[3,20]. For instance, a patient may possess a "brain age" aligned with their chronological age while exhibiting "accelerated heart age". This mosaicism suggests that while blood-based epigenetic clocks provide a powerful systemic average, the future of diagnostics lies in Multi-Organ Aging Profiles[20].

Standardization and Divergence- The current landscape is saturated with competing aging clocks. A major limitation is the lack of cross-platform standardization; the same individual can receive significantly different BA scores depending on whether the estimator uses DNA methylation or clinical biomarkers[21,22]. This "clock divergence" necessitates the development of a Universal Aging Index—a standardized, weighted composite of various omic layers.

Socioeconomic and Ethical Considerations- The high cost of high-throughput sequencing for epigenetic testing (often exceeding $500) poses a risk of "longevity inequality"[23]. If biological age monitoring remains a luxury, the healthspan gap between socioeconomic classes will widen. The efficacy of AI models in predicting BA from inexpensive, routine blood panels is a crucial step toward democratizing these metrics[19].

Future Scope- As we move through 2026, the integration of Continuous Biological Monitoring is becoming a reality. The future involves:

- **Precision Prevention:** Triggering medical screenings based on biological

milestones (e.g., a "biological age of 50") rather than birthdays[5].

- **Surrogate Endpoints:** Using BA to evaluate the efficacy of senolytics and longevity interventions in months rather than years, accelerating drug discovery[24].
- **Bio-Insurance:** Integrating BA into personalized health assessments to incentivize lifestyle modifications[25].

CONCLUSION

Biological age represents a paradigm shift in preventative healthcare. By moving beyond chronological milestones, clinicians can identify at-risk "fast agers" decades before clinical symptoms appear. As AI continues to refine multi-omic integration, BA will serve as the "gold standard" vital sign for assessing the efficacy of anti-aging interventions and personalizing the human healthspan.

REVIEW ARTICLE

REFERENCES

1. Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., Rando, T. A., Richardson, A., Schadt, E. E., Wyss-Coray, T., & Sierra, F. (2014). Geroscience: Linking aging to chronic disease. Cell, 159(4), 709–713. https://doi.org/10.1016/j.cell.2014.10.039

2. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194–1217. https://doi.org/10.1016/j.cell.2013.05.039

3. Ferrucci, L., Gonzalez-Freire, M., Fabbri, E., Simonsick, E., Tanaka, T., Moore, Z., Salimi, S., Sierra, F., & de Cabo, R. (2020). Measuring biological aging in humans: A quest. Aging Cell, 19(2), Article e13080. https://doi.org/10.1111/acel.13080

4. Levine, M. E. (2013). Modeling the rate of senescence: Can estimated biological age predict mortality more accurately than chronological age? The Journals of Gerontology: Series A, 68(6), 667–674. https://doi.org/10.1093/gerona/gls233

5. Jylhävä, J., Pedersen, N. L., & Hägg, S. (2017). Biological age predictors: The status quo and future outlook. EBioMedicine, 21, 29–36. https://doi.org/10.1016/j.ebiom.2017.05.046

6. Galkin, F., Mamoshina, P., Aliper, A., de Magalhães, J. P., Gladyshev, V. N., & Zhavoronkov, A. (2022). Bio-learn: An open-source library for biological age biomarkers. Nature Aging, 2, 1083–1086. https://doi.org/10.1038/s43587-022-00302-8

7. Klemera, P., & Doubal, S. (2006). A new approach to the concept and computation of biological age. Biogerontology, 7(1), 1–12. https://doi.org/10.1007/s10522-005-2702-2

8. Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Hou, L., Baccarelli, A. A., Stewart, J. D., Li, Y., Whitsel, E. A., Wilson, J. G., Reiner, A. P., Aviv, A., Lohman, K., Liu, Y., Ferrucci, L., & Horvath, S. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging, 10(4), 573–591. https://doi.org/10.18632/aging.101414

9. Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biology, 14(10), R115. https://doi.org/10.1186/gb-2013-14-10-r115

10. Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., Klotzle, B., Bibikova, M., Fan, J. B., Gao, Y., Deconde, R., Chen, M., Rajapakse, I., Friend, S., Ideker, T., & Zhang, K. (2013). Genome-wide methylation profiles reveal quantitative views of human aging rates. Molecular Cell, 49(2), 359–367. https://doi.org/10.1016/j.molcel.2012.10.016

11. Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., Hou, L., Baccarelli, A. A., Li, Y., Stewart, J. D., Whitsel, E. A., Assimes, T. L., Ferrucci, L., & Horvath, S. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging, 11(2), 303–327. https://doi.org/10.18632/aging.101684

REVIEW ARTICLE

12. Belsky, D. W., Caspi, A., Corcoran, D. L., Sugden, K., Poulton, R., Arseneault, L., Baccarelli, A., Chamarti, K., Gao, X., Hannon, E., Harrington, H. L., Hogan, S., Houts, R., Kothari, M., Moffitt, T. E., Rasmussen, L. J. H., Williams, B., & Danese, A. (2022). DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife, 11, e73420. https://doi.org/10.7554/eLife.73420

13. Wang, T., Xia, X., Li, B., & Wang, Y. (2022). Integrating multi-omics data for biological age estimation. Frontiers in Genetics, 13, Article 905453. https://doi.org/10.3389/fgene.2022.905453

14. Mamoshina, P., Volosnikova, M., Ozerov, I. V., Putin, E., Skibina, E., Cortese, F., & Zhavoronkov, A. (2018). Machine learning on human muscle transcriptomic data for biomarker discovery and tissue-specific drug target identification. Scientific Reports, 8, Article 2697. https://doi.org/10.1038/s41598-018-20649-3

15. Jia, L., Rong, S. S., Tao, Q., Deng, Y., & Cheung, C. Y. (2023). Retinal age gap as a predictive biomarker for mortality risk. British Journal of Ophthalmology. Advance online publication. https://doi.org/10.1136/bjo-2022-322839

16. Bobrov, E., Georgievskaya, A., Kiselev, K., Sevastopolsky, A., Zhavoronkov, A., Gurov, S., Rudakov, K., Del Pilar Bonilla Tobar, M., Jaspers, S., Clemann, S., & Putin, E. (2018). PhotoAgeClock: Deep learning algorithms for development of non-invasive visual biomarkers of aging. Aging, 10(11), 3249–3259. https://doi.org/10.18632/aging.101629

17. Waziry, R., Zhang, X., Sharp, T., et al. (2023). Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging, 3, 248–258. https://doi.org/10.1038/s43587-022-00357-7

18. Fahy, G. M., Brooke, R. T., Watson, J. P., Good, Z., Vasanawala, S. S., Maecker, H., Leipold, M. D., Lin, D. T. S., Kobor, M. S., & Horvath, S. (2019). Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell, 18(6), Article e13028. https://doi.org/10.1111/acel.13028

19. Putin, E., Mamoshina, P., Aliper, A., Korzinkin, M., Moskalev, A., Kolosov, A., Ostrovskiy, A., Cantor, C., Vijg, J., & Zhavoronkov, A. (2016). Deep biomarkers of human aging: Application of deep neural networks to biomarker development. Aging, 8(5), 1021–1033. https://doi.org/10.18632/aging.100968

20. Nie, J., Yang, X., Tang, W., et al. (2022). The multiscale architecture of biological aging. Cell, 185(26), 4962–4975.e26. https://doi.org/10.1016/j.cell.2022.11.008

21. Li, X., Ploner, A., Wang, Y., et al. (2020). The role of DNA methylation in aging. Aging Cell, 19(11), Article e13153. https://doi.org/10.1111/acel.13153

22. Nwanaji-Enwerem, J. U., Colicino, E., Trevisi, L., et al. (2021). Evolving limitations and opportunities of epigenetic clocks. Trends in

Genetics, 37(3), 205–222. https://doi.org/10.1016/j.tig.2020.11.003

23. Parker, D., Wilson, R., & Brown, M. (2020). Economic and social implications of aging clocks. Journal of Social Policy, 49(2), 321–338.

24. Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., & Kirkland, J. L. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label pilot study. EBioMedicine, 40, 554–563. https://doi.org/10.1016/j.ebiom.2018.12.052

25. Sano Genetics. (2025). Emerging trends and future research areas in aging and longevity. Annual Review of Geroscience.